Axcan To Ax Itax?: Phase III Data Put Functional Dyspepsia Program In Jeopardy
This article was originally published in The Pink Sheet Daily
Executive SummaryFirm awaits further analysis of international study and second Phase III trial data due by June before pulling plug; diabetic gastropathy program to continue.
You may also be interested in...
Ernst & Young annual report highlights the importance of emerging “patient-empowering” and “information-leveraging” technologies, and their power to drive health care efficiencies.